Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7743)	1/16/2003 3:11:16 PM
From: Jacob Snyder	Read Replies (3) \| Respond to of 52153

<<expected 2005 earnings for the "big 9" biotechs will be almost double 2002 earnings>> The problem here, is: 1. foreward earnings forecasts are random numbers. Neither you nor I have any idea which blockbuster will be the next one to dissolve heart valves. Or which drug put on the market targetted at a small niche, gets used to cure diabetes or depression. That is, nobody has a decent track record of accurate forecasts, and so current forecasts should be used as a gauge of current sentiment, and nothing else; i.e., if the forecasts are rosy, that's a sell signal. 2. even if those forecasts were accurate, there is zero correlation between biotech earnings and stock prices. The industry just isn't mature enough, yet, for that. You can use trailing, 12M foreward, 5-year forecasts, whatever, the picture is the same. 3. even if there was a correlation, and the last-5-years of data showed it, that time period is full of events on the thin edge of the bell-shaped-curve, so most of the data points should be thrown out. 4. even if there was correlation, and even if the recent (5Y) past predicted the future, correlation isn't causation. Until this industry gets mature enough that cash flow supports research/development/marketting costs, profits probably won't be helpful in predicting stock prices.

To: Biomaven who wrote (7743)	1/18/2003 11:28:52 AM
From: Sam Citron	Read Replies (1) \| Respond to of 52153

Although I have closed out most of my biotech hedges, I have also used the last few month's strength in biotech to come completely off margin (and then some) and I retain a short on the QQQ as a hedge. Congratulations. Your hedge program certainly paid handsome dividends yesterday. I have several questions about your hedge strategy and vehicles, should you be so kind as to deem them response-worthy. (1) What's your current hedge ratio and how has it varied over, say, the past 5 years? (2) You said earlier that you closed out your BBH short mainly in response to favorable top tier fundamentals. How do you determine what hedges to employ and when to employ them? (3) What other hedges besides QQQ and BBH have you employed in the past? (4) Have you calculated the value added by your hedge program? [BTW, I am enjoying Complications. Thanks again for the recommendation.] Sam